Group A and C Meningococcal Polysaccharide Vaccine Industry Research Report 2025

Summary

According to APO Research, the global Group A and C Meningococcal Polysaccharide Vaccine market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.

North American market for Group A and C Meningococcal Polysaccharide Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Group A and C Meningococcal Polysaccharide Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Group A and C Meningococcal Polysaccharide Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Group A and C Meningococcal Polysaccharide Vaccine include Pfizer, Sanofi Pasteur, AIM Bio, Chengda Biotechnology, GlaxoSmithKline, Cansino Biologics, Sinovac, Lanzhou Institute of Biological Products and Royal (Wuxi) Bio-Pharmaceutical, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Group A and C Meningococcal Polysaccharide Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Group A and C Meningococcal Polysaccharide Vaccine.

The report will help the Group A and C Meningococcal Polysaccharide Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

The Group A and C Meningococcal Polysaccharide Vaccine market size, estimations, and forecasts are provided in terms of sales volume (Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Group A and C Meningococcal Polysaccharide Vaccine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.

Group A and C Meningococcal Polysaccharide Vaccine Segment by Company

Pfizer
Sanofi Pasteur
AIM Bio
Chengda Biotechnology
GlaxoSmithKline
Cansino Biologics
Sinovac
Lanzhou Institute of Biological Products
Royal (Wuxi) Bio-Pharmaceutical
Merck & Co.
Toyouvax
Walvax
Zhifei Biological
Group A and C Meningococcal Polysaccharide Vaccine Segment by Type

Polysaccharide-protein Conjugate Vaccine
Polysaccharide Vaccine
Group A and C Meningococcal Polysaccharide Vaccine Segment by Application

Hospital
Centers for Disease Control and Prevention
Others
Group A and C Meningococcal Polysaccharide Vaccine Segment by Region

North America

United States
Canada
Mexico
Europe

Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific

China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America

Brazil
Argentina
Chile
Middle East & Africa

Egypt
South Africa
Israel
Türkiye
GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Group A and C Meningococcal Polysaccharide Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Group A and C Meningococcal Polysaccharide Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Group A and C Meningococcal Polysaccharide Vaccine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Group A and C Meningococcal Polysaccharide Vaccine manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Group A and C Meningococcal Polysaccharide Vaccine by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Group A and C Meningococcal Polysaccharide Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.


1 Preface
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 Market Overview
2.1 Product Definition
2.2 Global Market Growth Prospects
2.2.1 Global Group A and C Meningococcal Polysaccharide Vaccine Market Size (2020-2031)
2.2.2 Global Group A and C Meningococcal Polysaccharide Vaccine Sales (2020-2031)
2.2.3 Global Group A and C Meningococcal Polysaccharide Vaccine Market Average Price (2020-2031)
2.3 Group A and C Meningococcal Polysaccharide Vaccine by Type
2.3.1 Market Value Comparison by Type (2020 VS 2024 VS 2031) & (US$ Million)
2.3.2 Polysaccharide-protein Conjugate Vaccine
2.3.3 Polysaccharide Vaccine
2.4 Group A and C Meningococcal Polysaccharide Vaccine by Application
2.4.1 Market Value Comparison by Application (2020 VS 2024 VS 2031)
2.4.2 Hospital
2.4.3 Centers for Disease Control and Prevention
2.4.4 Others
3 Market Competitive Landscape by Manufacturers
3.1 Global Group A and C Meningococcal Polysaccharide Vaccine Market Competitive Situation by Manufacturers (2020 Versus 2024)
3.2 Global Group A and C Meningococcal Polysaccharide Vaccine Sales (Units) of Manufacturers (2020-2025)
3.3 Global Group A and C Meningococcal Polysaccharide Vaccine Revenue of Manufacturers (2020-2025)
3.4 Global Group A and C Meningococcal Polysaccharide Vaccine Average Price by Manufacturers (2020-2025)
3.5 Global Group A and C Meningococcal Polysaccharide Vaccine Industry Ranking, 2023 VS 2024 VS 2025
3.6 Global Manufacturers of Group A and C Meningococcal Polysaccharide Vaccine, Manufacturing Sites & Headquarters
3.7 Global Manufacturers of Group A and C Meningococcal Polysaccharide Vaccine, Product Type & Application
3.8 Global Manufacturers of Group A and C Meningococcal Polysaccharide Vaccine, Established Date
3.9 Global Group A and C Meningococcal Polysaccharide Vaccine Market CR5 and HHI
3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
4.1 Pfizer
4.1.1 Pfizer Company Information
4.1.2 Pfizer Business Overview
4.1.3 Pfizer Group A and C Meningococcal Polysaccharide Vaccine Sales, Revenue and Gross Margin (2020-2025)
4.1.4 Pfizer Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio
4.1.5 Pfizer Recent Developments
4.2 Sanofi Pasteur
4.2.1 Sanofi Pasteur Company Information
4.2.2 Sanofi Pasteur Business Overview
4.2.3 Sanofi Pasteur Group A and C Meningococcal Polysaccharide Vaccine Sales, Revenue and Gross Margin (2020-2025)
4.2.4 Sanofi Pasteur Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio
4.2.5 Sanofi Pasteur Recent Developments
4.3 AIM Bio
4.3.1 AIM Bio Company Information
4.3.2 AIM Bio Business Overview
4.3.3 AIM Bio Group A and C Meningococcal Polysaccharide Vaccine Sales, Revenue and Gross Margin (2020-2025)
4.3.4 AIM Bio Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio
4.3.5 AIM Bio Recent Developments
4.4 Chengda Biotechnology
4.4.1 Chengda Biotechnology Company Information
4.4.2 Chengda Biotechnology Business Overview
4.4.3 Chengda Biotechnology Group A and C Meningococcal Polysaccharide Vaccine Sales, Revenue and Gross Margin (2020-2025)
4.4.4 Chengda Biotechnology Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio
4.4.5 Chengda Biotechnology Recent Developments
4.5 GlaxoSmithKline
4.5.1 GlaxoSmithKline Company Information
4.5.2 GlaxoSmithKline Business Overview
4.5.3 GlaxoSmithKline Group A and C Meningococcal Polysaccharide Vaccine Sales, Revenue and Gross Margin (2020-2025)
4.5.4 GlaxoSmithKline Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio
4.5.5 GlaxoSmithKline Recent Developments
4.6 Cansino Biologics
4.6.1 Cansino Biologics Company Information
4.6.2 Cansino Biologics Business Overview
4.6.3 Cansino Biologics Group A and C Meningococcal Polysaccharide Vaccine Sales, Revenue and Gross Margin (2020-2025)
4.6.4 Cansino Biologics Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio
4.6.5 Cansino Biologics Recent Developments
4.7 Sinovac
4.7.1 Sinovac Company Information
4.7.2 Sinovac Business Overview
4.7.3 Sinovac Group A and C Meningococcal Polysaccharide Vaccine Sales, Revenue and Gross Margin (2020-2025)
4.7.4 Sinovac Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio
4.7.5 Sinovac Recent Developments
4.8 Lanzhou Institute of Biological Products
4.8.1 Lanzhou Institute of Biological Products Company Information
4.8.2 Lanzhou Institute of Biological Products Business Overview
4.8.3 Lanzhou Institute of Biological Products Group A and C Meningococcal Polysaccharide Vaccine Sales, Revenue and Gross Margin (2020-2025)
4.8.4 Lanzhou Institute of Biological Products Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio
4.8.5 Lanzhou Institute of Biological Products Recent Developments
4.9 Royal (Wuxi) Bio-Pharmaceutical
4.9.1 Royal (Wuxi) Bio-Pharmaceutical Company Information
4.9.2 Royal (Wuxi) Bio-Pharmaceutical Business Overview
4.9.3 Royal (Wuxi) Bio-Pharmaceutical Group A and C Meningococcal Polysaccharide Vaccine Sales, Revenue and Gross Margin (2020-2025)
4.9.4 Royal (Wuxi) Bio-Pharmaceutical Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio
4.9.5 Royal (Wuxi) Bio-Pharmaceutical Recent Developments
4.10 Merck & Co.
4.10.1 Merck & Co. Company Information
4.10.2 Merck & Co. Business Overview
4.10.3 Merck & Co. Group A and C Meningococcal Polysaccharide Vaccine Sales, Revenue and Gross Margin (2020-2025)
4.10.4 Merck & Co. Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio
4.10.5 Merck & Co. Recent Developments
4.11 Toyouvax
4.11.1 Toyouvax Company Information
4.11.2 Toyouvax Business Overview
4.11.3 Toyouvax Group A and C Meningococcal Polysaccharide Vaccine Sales, Revenue and Gross Margin (2020-2025)
4.11.4 Toyouvax Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio
4.11.5 Toyouvax Recent Developments
4.12 Walvax
4.12.1 Walvax Company Information
4.12.2 Walvax Business Overview
4.12.3 Walvax Group A and C Meningococcal Polysaccharide Vaccine Sales, Revenue and Gross Margin (2020-2025)
4.12.4 Walvax Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio
4.12.5 Walvax Recent Developments
4.13 Zhifei Biological
4.13.1 Zhifei Biological Company Information
4.13.2 Zhifei Biological Business Overview
4.13.3 Zhifei Biological Group A and C Meningococcal Polysaccharide Vaccine Sales, Revenue and Gross Margin (2020-2025)
4.13.4 Zhifei Biological Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio
4.13.5 Zhifei Biological Recent Developments
5 Global Group A and C Meningococcal Polysaccharide Vaccine Market Scenario by Region
5.1 Global Group A and C Meningococcal Polysaccharide Vaccine Market Size by Region: 2020 VS 2024 VS 2031
5.2 Global Group A and C Meningococcal Polysaccharide Vaccine Sales by Region: 2020-2031
5.2.1 Global Group A and C Meningococcal Polysaccharide Vaccine Sales by Region: 2020-2025
5.2.2 Global Group A and C Meningococcal Polysaccharide Vaccine Sales by Region: 2026-2031
5.3 Global Group A and C Meningococcal Polysaccharide Vaccine Revenue by Region: 2020-2031
5.3.1 Global Group A and C Meningococcal Polysaccharide Vaccine Revenue by Region: 2020-2025
5.3.2 Global Group A and C Meningococcal Polysaccharide Vaccine Revenue by Region: 2026-2031
5.4 North America Group A and C Meningococcal Polysaccharide Vaccine Market Facts & Figures by Country
5.4.1 North America Group A and C Meningococcal Polysaccharide Vaccine Market Size by Country: 2020 VS 2024 VS 2031
5.4.2 North America Group A and C Meningococcal Polysaccharide Vaccine Sales by Country (2020-2031)
5.4.3 North America Group A and C Meningococcal Polysaccharide Vaccine Revenue by Country (2020-2031)
5.4.4 United States
5.4.5 Canada
5.4.6 Mexico
5.5 Europe Group A and C Meningococcal Polysaccharide Vaccine Market Facts & Figures by Country
5.5.1 Europe Group A and C Meningococcal Polysaccharide Vaccine Market Size by Country: 2020 VS 2024 VS 2031
5.5.2 Europe Group A and C Meningococcal Polysaccharide Vaccine Sales by Country (2020-2031)
5.5.3 Europe Group A and C Meningococcal Polysaccharide Vaccine Revenue by Country (2020-2031)
5.5.4 Germany
5.5.5 France
5.5.6 U.K.
5.5.7 Italy
5.5.8 Russia
5.5.9 Spain
5.5.10 Netherlands
5.5.11 Switzerland
5.5.12 Sweden
5.5.13 Poland
5.6 Asia Pacific Group A and C Meningococcal Polysaccharide Vaccine Market Facts & Figures by Country
5.6.1 Asia Pacific Group A and C Meningococcal Polysaccharide Vaccine Market Size by Country: 2020 VS 2024 VS 2031
5.6.2 Asia Pacific Group A and C Meningococcal Polysaccharide Vaccine Sales by Country (2020-2031)
5.6.3 Asia Pacific Group A and C Meningococcal Polysaccharide Vaccine Revenue by Country (2020-2031)
5.6.4 China
5.6.5 Japan
5.6.6 South Korea
5.6.7 India
5.6.8 Australia
5.6.9 Taiwan
5.6.10 Southeast Asia
5.7 South America Group A and C Meningococcal Polysaccharide Vaccine Market Facts & Figures by Country
5.7.1 South America Group A and C Meningococcal Polysaccharide Vaccine Market Size by Country: 2020 VS 2024 VS 2031
5.7.2 South America Group A and C Meningococcal Polysaccharide Vaccine Sales by Country (2020-2031)
5.7.3 South America Group A and C Meningococcal Polysaccharide Vaccine Revenue by Country (2020-2031)
5.7.4 Brazil
5.7.5 Argentina
5.7.6 Chile
5.8 Middle East and Africa Group A and C Meningococcal Polysaccharide Vaccine Market Facts & Figures by Country
5.8.1 Middle East and Africa Group A and C Meningococcal Polysaccharide Vaccine Market Size by Country: 2020 VS 2024 VS 2031
5.8.2 Middle East and Africa Group A and C Meningococcal Polysaccharide Vaccine Sales by Country (2020-2031)
5.8.3 Middle East and Africa Group A and C Meningococcal Polysaccharide Vaccine Revenue by Country (2020-2031)
5.8.4 Egypt
5.8.5 South Africa
5.8.6 Israel
5.8.7 Türkiye
5.8.8 GCC Countries
6 Segment by Type
6.1 Global Group A and C Meningococcal Polysaccharide Vaccine Sales by Type (2020-2031)
6.1.1 Global Group A and C Meningococcal Polysaccharide Vaccine Sales by Type (2020-2031) & (Units)
6.1.2 Global Group A and C Meningococcal Polysaccharide Vaccine Sales Market Share by Type (2020-2031)
6.2 Global Group A and C Meningococcal Polysaccharide Vaccine Revenue by Type (2020-2031)
6.2.1 Global Group A and C Meningococcal Polysaccharide Vaccine Sales by Type (2020-2031) & (US$ Million)
6.2.2 Global Group A and C Meningococcal Polysaccharide Vaccine Revenue Market Share by Type (2020-2031)
6.3 Global Group A and C Meningococcal Polysaccharide Vaccine Price by Type (2020-2031)
7 Segment by Application
7.1 Global Group A and C Meningococcal Polysaccharide Vaccine Sales by Application (2020-2031)
7.1.1 Global Group A and C Meningococcal Polysaccharide Vaccine Sales by Application (2020-2031) & (Units)
7.1.2 Global Group A and C Meningococcal Polysaccharide Vaccine Sales Market Share by Application (2020-2031)
7.2 Global Group A and C Meningococcal Polysaccharide Vaccine Revenue by Application (2020-2031)
7.2.1 Global Group A and C Meningococcal Polysaccharide Vaccine Sales by Application (2020-2031) & (US$ Million)
7.2.2 Global Group A and C Meningococcal Polysaccharide Vaccine Revenue Market Share by Application (2020-2031)
7.3 Global Group A and C Meningococcal Polysaccharide Vaccine Price by Application (2020-2031)
8 Value Chain and Sales Channels Analysis of the Market
8.1 Group A and C Meningococcal Polysaccharide Vaccine Value Chain Analysis
8.1.1 Group A and C Meningococcal Polysaccharide Vaccine Key Raw Materials
8.1.2 Raw Materials Key Suppliers
8.1.3 Group A and C Meningococcal Polysaccharide Vaccine Production Mode & Process
8.2 Group A and C Meningococcal Polysaccharide Vaccine Sales Channels Analysis
8.2.1 Direct Comparison with Distribution Share
8.2.2 Group A and C Meningococcal Polysaccharide Vaccine Distributors
8.2.3 Group A and C Meningococcal Polysaccharide Vaccine Customers
9 Global Group A and C Meningococcal Polysaccharide Vaccine Analyzing Market Dynamics
9.1 Group A and C Meningococcal Polysaccharide Vaccine Industry Trends
9.2 Group A and C Meningococcal Polysaccharide Vaccine Industry Drivers
9.3 Group A and C Meningococcal Polysaccharide Vaccine Industry Opportunities and Challenges
9.4 Group A and C Meningococcal Polysaccharide Vaccine Industry Restraints
10 Report Conclusion
11 Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings